title: Syndecan-1 overexpression is associated with nonluminal subtypes and poor prognosis in advanced breast cancer.
abstract: OBJECTIVE
  Syndecan-1 expression is decreased in diverse tumor types but remains controversial in breast carcinomas. The goal of the study was to examine syndecan-1 expression in breast carcinoma and its prognostic significance.
  
  
  METHODS
  The epithelial expression of syndecan-1 was examined in tissue microarrays constructed from 62 consecutive breast carcinoma cases diagnosed between 1997 and 2004 with distant organ metastasis and 10 consecutive control cases (breast carcinoma with no distant metastasis after at least 8 years of follow-up). The prognostic significance of syndecan-1 was estimated by utilizing a Cox proportional hazards regression model.
  
  
  RESULTS
  Among tumors with distant metastasis, syndecan-1 expression was significantly associated with a higher histologic grade and inversely related to hormonal receptor status. The HER2 subtype and triple-negative carcinomas exhibited markedly higher syndecan-1 levels than those of luminal subtypes, while the latter remained significantly higher than nonmetastatic control cases. Furthermore, high syndecan-1 expression had a negative impact on both overall and disease-free survival rates.
  
  
  CONCLUSIONS
  These findings suggest that syndecan-1 may regulate breast cancer cell behavior and thus deserves further investigation to ascertain its potential as a therapeutic target, especially in metastatic, triple-negative carcinomas.
authors.affiliation: Dept of Pathology, University of Alabama at Birmingham, NP 3542, 619 19th St, South Birmingham, AL 35249-7331; swei@uab.edu.
authors.forename: Thuy L
authors.initials: TL
authors.lastname: Nguyen
authors.forename: William E
authors.initials: WE
authors.lastname: Grizzle
authors.forename: Kui
authors.initials: K
authors.lastname: Zhang
authors.forename: Omar
authors.initials: O
authors.lastname: Hameed
authors.forename: Gene P
authors.initials: GP
authors.lastname: Siegal
authors.forename: Shi
authors.initials: S
authors.lastname: Wei
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism / Q000401:mortality / Q000556:secondary*; D018275:Carcinoma, Lobular / Q000378:metabolism / Q000401:mortality / Q000556:secondary*; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008875:Middle Aged; D060787:Neoplasm Grading; D011379:Prognosis; D016016:Proportional Hazards Models; D015996:Survival Rate; D053668:Syndecan-1 / Q000378:metabolism*; D013714:Tennessee / Q000453:epidemiology; D046888:Tissue Array Analysis
chemical_list: D014408:Biomarkers, Tumor; C508241:SDC1 protein, human; D053668:Syndecan-1
keywords: Breast cancer; Prognosis; Subtype; Syndecan-1